The contribution of the sphingosine 1-phosphate signaling pathway to chronic kidney diseases: recent findings and new perspectives.
Diabetes mellitus
Fibrosis
Glomerulosclerosis
Inflammation
Sphingosine kinase
TGF-β
Journal
Pflugers Archiv : European journal of physiology
ISSN: 1432-2013
Titre abrégé: Pflugers Arch
Pays: Germany
ID NLM: 0154720
Informations de publication
Date de publication:
09 Oct 2024
09 Oct 2024
Historique:
received:
25
09
2024
accepted:
30
09
2024
revised:
26
09
2024
medline:
10
10
2024
pubmed:
10
10
2024
entrez:
9
10
2024
Statut:
aheadofprint
Résumé
Chronic kidney disease (CKD) is a multifactorial condition with diverse etiologies, such as diabetes mellitus, hypertension, and genetic disorders, often culminating in end-stage renal disease (ESRD). A hallmark of CKD progression is kidney fibrosis, characterized by the excessive accumulation of extracellular matrix components, for which there is currently no effective anti-fibrotic therapy. Recent literature highlights the critical role of sphingosine 1-phosphate (S1P) signaling in CKD pathogenesis and renal fibrosis. This review provides an in-depth analysis of the latest findings on S1P metabolism and signaling in renal fibrosis and in specific CKDs, including diabetic nephropathy (DN), lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), Fabry disease (FD), and IgA nephropathy (IgAN). Emerging studies underscore the therapeutic potential of modulating S1P signaling with receptor modulators and inhibitors, such as fingolimod (FTY720) and more selective agents like ozanimod and cenerimod. Additionally, the current knowledge about the effects of established kidney protective therapies such as glucocorticoids and SGLT2 and ACE inhibitors on S1P signaling will be summarized. Furthermore, the review highlights the potential role of S1P as a biomarker for disease progression in CKD models, particularly in Fabry disease and diabetic nephropathy. Advanced technologies, including spatial transcriptomics, are further refining our understanding of S1P's role within specific kidney compartments. Collectively, these insights emphasize the need for continued research into S1P signaling pathways as promising targets for CKD treatment strategies.
Identifiants
pubmed: 39384640
doi: 10.1007/s00424-024-03029-5
pii: 10.1007/s00424-024-03029-5
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : LOEWE Initiative
ID : ACLF-I
Organisme : Deutsche Forschungsgemeinschaft
ID : 204083920, 259130777
Organisme : Deutsche Forschungsgemeinschaft
ID : 204083920, 259130777
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 310030_219605, 320030_219451
Informations de copyright
© 2024. The Author(s).
Références
Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, van Roomen C, Mirzaian M, Wijburg FA, Linthorst GE, Vedder AC, Rombach SM, Cox-Brinkman J, Somerharju P, Boot RG, Hollak CE, Brady RO, Poorthuis BJ (2008) Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A 105:2812–2817. https://doi.org/10.1073/pnas.0712309105
doi: 10.1073/pnas.0712309105
pubmed: 18287059
pmcid: 2268542
Akbari M, West JD, Doerr N, Kipp KR, Marhamati N, Vuong S, Wang Y, Rinschen MM, Talbot JJ, Wessely O, Weimbs T (2022) Restoration of atypical protein kinase C ζ function in autosomal dominant polycystic kidney disease ameliorates disease progression. Proc Natl Acad Sci U S A 119:e2121267119. https://doi.org/10.1073/pnas.2121267119
doi: 10.1073/pnas.2121267119
pubmed: 35867829
pmcid: 9335328
Alemany R, van Koppen CJ, Danneberg K, Ter Braak M, Meyer Zu Heringdorf D (2007) Regulation and functional roles of sphingosine kinases. Naunyn Schmiedebergs Arch Pharmacol 374:413–428. https://doi.org/10.1007/s00210-007-0132-3
Ando S, Amano H, Amano E, Minowa K, Watanabe T, Nakano S, Nakiri Y, Morimoto S, Tokano Y, Lin Q, Hou R, Ohtsuji M, Tsurui H, Hirose S, Takasaki Y (2010) FTY720 exerts a survival advantage through the prevention of end-stage glomerular inflammation in lupus-prone BXSB mice. Biochem Biophys Res Commun 394:804–810. https://doi.org/10.1016/j.bbrc.2010.03.078
doi: 10.1016/j.bbrc.2010.03.078
pubmed: 20233577
Antoon JW, White MD, Meacham WD, Slaughter EM, Muir SE, Elliott S, Rhodes LV, Ashe HB, Wiese TE, Smith CD, Burow ME, Beckman BS (2010) Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640. Endocrinology 151:5124–5135. https://doi.org/10.1210/en.2010-0420
doi: 10.1210/en.2010-0420
pubmed: 20861237
pmcid: 2954724
Bagheri Y, Ahmadian E, Hejazian SM, Raeesi M, Zununi Vahed S, Ardalan M (2024) The effect of fingolimod on renal ischemia/reperfusion injury in a rat model. Curr Mol Pharmacol 17:e250823220363. https://doi.org/10.2174/1874467217666230825113406
doi: 10.2174/1874467217666230825113406
pubmed: 37622553
Bajwa A, Huang L, Kurmaeva E, Ye H, Dondeti KR, Chroscicki P, Foley LS, Balogun ZA, Alexander KJ, Park H (2017) Sphingosine kinase 2 deficiency attenuates kidney fibrosis via IFN-γ. J Am Soc Nephrol 28:1145
doi: 10.1681/ASN.2016030306
pubmed: 27799486
Bajwa A, Jo S-K, Ye H, Huang L, Dondeti KR, Rosin DL, Haase VH, Macdonald TL, Lynch KR, Okusa MD (2010) Activation of sphingosine-1-phosphate 1 receptor in the proximal tubule protects against ischemia-reperfusion injury. J Am Soc Nephrol 21:955. https://doi.org/10.1681/ASN.2009060662
doi: 10.1681/ASN.2009060662
pubmed: 20338995
pmcid: 2900956
Bajwa A, Rosin DL, Chroscicki P, Lee S, Dondeti K, Ye H, Kinsey GR, Stevens BK, Jobin K, Kenwood BM, Hoehn KL, Lynch KR, Okusa MD (2015) Sphingosine 1-phosphate receptor-1 enhances mitochondrial function and reduces cisplatin-induced tubule injury. J Am Soc Nephrol 26:908–925. https://doi.org/10.1681/ASN.2013121351
doi: 10.1681/ASN.2013121351
pubmed: 25145931
Bekpinar S, Yenidunya G, Gurdol F, Unlucerci Y, Aycan-Ustyol E, Dinccag N (2015) The effect of nephropathy on plasma sphingosine 1-phosphate concentrations in patients with type 2 diabetes. Clin Biochem 48:1264–1267
doi: 10.1016/j.clinbiochem.2015.08.001
pubmed: 26255120
Bery AI, Shepherd HM, Li W, Krupnick AS, Gelman AE, Kreisel D (2022) Role of tertiary lymphoid organs in the regulation of immune responses in the periphery. Cell Mol Life Sci 79:359. https://doi.org/10.1007/s00018-022-04388-x
doi: 10.1007/s00018-022-04388-x
pubmed: 35689679
pmcid: 9188279
Blanchard O, Stepanovska B, Starck M, Erhardt M, Römer I, Meyer Zu Heringdorf D, Pfeilschifter J, Zangemeister-Wittke U, Huwiler A (2018) Downregulation of the S1P transporter spinster homology protein 2 (Spns2) exerts an anti-fibrotic and anti-inflammatory effect in human renal proximal tubular epithelial cells. Int J Mol Sci 19:1498. https://doi.org/10.3390/ijms19051498
Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L (1967) Enzymatic defect in Fabry’s disease. Ceramidetrihexosidase deficiency N Engl J Med 276:1163–1167. https://doi.org/10.1056/NEJM196705252762101
doi: 10.1056/NEJM196705252762101
pubmed: 6023233
Brakch N, Dormond O, Bekri S, Golshayan D, Correvon M, Mazzolai L, Steinmann B, Barbey F (2010) Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease. Eur Heart J 31:67–76. https://doi.org/10.1093/eurheartj/ehp387
doi: 10.1093/eurheartj/ehp387
pubmed: 19773225
Brunkhorst R, Pfeilschifter W, Patyna S, Büttner S, Eckes T, Trautmann S, Thomas D, Pfeilschifter J, Koch A (2018) Preanalytical biases in the measurement of human blood sphingolipids. Int J Mol Sci 19:1390. https://doi.org/10.3390/ijms19051390
doi: 10.3390/ijms19051390
pubmed: 29735920
pmcid: 5983773
Burla B, Oh J, Nowak A, Piraud N, Meyer E, Mei D, Bendt AK, Studt J-D, Frey BM, Torta F, Wenk MR, Krayenbuehl P-A (2024) Plasma and platelet lipidome changes in Fabry disease. Clin Chim Acta 562:119833. https://doi.org/10.1016/j.cca.2024.119833
doi: 10.1016/j.cca.2024.119833
pubmed: 38955246
Checa A, Idborg H, Zandian A, Sar DG, Surowiec I, Trygg J, Svenungsson E, Jakobsson P-J, Nilsson P, Gunnarsson I, Wheelock CE (2017) Dysregulations in circulating sphingolipids associate with disease activity indices in female patients with systemic lupus erythematosus: a cross-sectional study. Lupus 26:1023–1033. https://doi.org/10.1177/0961203316686707
doi: 10.1177/0961203316686707
pubmed: 28134039
Chen C, Gong W, Li C, Xiong F, Wang S, Huang J, Wang Y, Chen Z, Chen Q, Liu P (2017) Sphingosine kinase 1 mediates AGEs-induced fibronectin upregulation in diabetic nephropathy. Oncotarget 8:78660
doi: 10.18632/oncotarget.20205
pubmed: 29108256
pmcid: 5667989
Choi Y-J, Saba JD (2019) Sphingosine phosphate lyase insufficiency syndrome (SPLIS): a novel inborn error of sphingolipid metabolism. Adv Biol Regul 71:128–140. https://doi.org/10.1016/j.jbior.2018.09.004
doi: 10.1016/j.jbior.2018.09.004
pubmed: 30274713
D’Agati VD, Kaskel FJ, Falk RJ (2011) Focal segmental glomerulosclerosis. N Engl J Med 365:2398–2411. https://doi.org/10.1056/NEJMra1106556
doi: 10.1056/NEJMra1106556
pubmed: 22187987
De Vriese AS, Wetzels JF, Glassock RJ, Sethi S, Fervenza FC (2021) Therapeutic trials in adult FSGS: lessons learned and the road forward. Nat Rev Nephrol 17:619–630. https://doi.org/10.1038/s41581-021-00427-1
doi: 10.1038/s41581-021-00427-1
pubmed: 34017116
pmcid: 8136112
Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, Grabowski G, Packman S, Wilcox WR (2003) Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138:338–346. https://doi.org/10.7326/0003-4819-138-4-200302180-00014
doi: 10.7326/0003-4819-138-4-200302180-00014
pubmed: 12585833
Ding B-S, Yang D, Swendeman SL, Christoffersen C, Nielsen LB, Friedman SL, Powell CA, Hla T, Cao Z (2020) Aging suppresses sphingosine-1-phosphate chaperone ApoM in circulation resulting in maladaptive organ repair. Dev Cell 53:677-690.e4. https://doi.org/10.1016/j.devcel.2020.05.024
doi: 10.1016/j.devcel.2020.05.024
pubmed: 32544390
pmcid: 7607448
Ding G, Sonoda H, Yu H, Kajimoto T, Goparaju SK, Jahangeer S, Okada T, Nakamura S (2007) Protein kinase D-mediated phosphorylation and nuclear export of sphingosine kinase 2*. J Biol Chem 282:27493–27502. https://doi.org/10.1074/jbc.M701641200
doi: 10.1074/jbc.M701641200
pubmed: 17635916
Donoviel MS, Hait NC, Ramachandran S, Maceyka M, Takabe K, Milstien S, Oravecz T, Spiegel S (2015) Spinster 2, a sphingosine-1-phosphate transporter, plays a critical role in inflammatory and autoimmune diseases. FASEB J 29:5018–5028. https://doi.org/10.1096/fj.15-274936
doi: 10.1096/fj.15-274936
pubmed: 26324848
pmcid: 4653056
Drexler Y, Molina J, Mitrofanova A, Fornoni A, Merscher S (2021) Sphingosine-1-phosphate metabolism and signaling in kidney diseases. J Am Soc Nephrol 32:9
doi: 10.1681/ASN.2020050697
pubmed: 33376112
Du C, Ren Y, Yao F, Duan J, Zhao H, Du Y, Xiao X, Duan H, Shi Y (2017) Sphingosine kinase 1 protects renal tubular epithelial cells from renal fibrosis via induction of autophagy. Int J Biochem Cell Biol 90:17–28. https://doi.org/10.1016/j.biocel.2017.07.011
doi: 10.1016/j.biocel.2017.07.011
pubmed: 28733250
Eckes T, Patyna S, Koch A, Oftring A, Gauer S, Obermüller N, Schwalm S, Schaefer L, Chun J, Gröne H-J, Pfeilschifter J (2022) Sphingosine 1-phosphate receptor 5 (S1P5) knockout ameliorates adenine-induced nephropathy. Int J Mol Sci 23:3952. https://doi.org/10.3390/ijms23073952
doi: 10.3390/ijms23073952
pubmed: 35409312
pmcid: 8999641
Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, Pletcher MA, Smith AE, Tang K, Yuan C-W, Brown JC, Friedman J, He J, Heuton KR, Holmberg M, Patel DJ, Reidy P, Carter A, Cercy K, Chapin A, Douwes-Schultz D, Frank T, Goettsch F, Liu PY, Nandakumar V, Reitsma MB, Reuter V, Sadat N, Sorensen RJD, Srinivasan V, Updike RL, York H, Lopez AD, Lozano R, Lim SS, Mokdad AH, Vollset SE, Murray CJL (2018) Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet 392:2052–2090. https://doi.org/10.1016/S0140-6736(18)31694-5
doi: 10.1016/S0140-6736(18)31694-5
pubmed: 30340847
pmcid: 6227505
Förster A, Emmler T, Schwalm S, Ebadi M, Heringdorf DMZ, Nieuwenhuis B, Kleuser B, Huwiler A, Pfeilschifter J (2010) Glucocorticoids protect renal mesangial cells from apoptosis by increasing cellular sphingosine-1-phosphate. Kidney Int 77:870–879. https://doi.org/10.1038/ki.2010.62
doi: 10.1038/ki.2010.62
pubmed: 20375982
French KJ, Zhuang Y, Maines LW, Gao P, Wang W, Beljanski V, Upson JJ, Green CL, Keller SN, Smith CD (2010) Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J Pharmacol Exp Ther 333:129–139. https://doi.org/10.1124/jpet.109.163444
doi: 10.1124/jpet.109.163444
pubmed: 20061445
pmcid: 2846016
Fritzemeier R, Foster D, Peralta A, Payette M, Kharel Y, Huang T, Lynch KR, Santos WL (2022) Discovery of in vivo active sphingosine-1-phosphate transporter (Spns2) inhibitors. J Med Chem 65:7656–7681. https://doi.org/10.1021/acs.jmedchem.1c02171
doi: 10.1021/acs.jmedchem.1c02171
pubmed: 35609189
pmcid: 9733493
Fukuhara S, Simmons S, Kawamura S, Inoue A, Orba Y, Tokudome T, Sunden Y, Arai Y, Moriwaki K, Ishida J, Uemura A, Kiyonari H, Abe T, Fukamizu A, Hirashima M, Sawa H, Aoki J, Ishii M, Mochizuki N (2012) The sphingosine-1-phosphate transporter Spns2 expressed on endothelial cells regulates lymphocyte trafficking in mice. J Clin Invest 122:1416–1426. https://doi.org/10.1172/JCI60746
doi: 10.1172/JCI60746
pubmed: 22406534
pmcid: 3314466
Geoffroy K, Troncy L, Wiernsperger N, Lagarde M, El Bawab S (2005) Glomerular proliferation during early stages of diabetic nephropathy is associated with local increase of sphingosine-1-phosphate levels. FEBS Lett 579:1249–1254
doi: 10.1016/j.febslet.2004.12.094
pubmed: 15710421
Ghosh M, Thangada S, Dasgupta O, Khanna K, Yamase H, Kashgarian M, Hla T, Shapiro L, Ferrer F (2018) Cell-intrinsic sphingosine kinase 2 promotes macrophage polarization and renal inflammation in response to unilateral ureteral obstruction. PLoS ONE 13. https://doi.org/10.1371/journal.pone.0194053
Ghosh M, Thangada S, Dasgupta O, Khanna KM, Yamase HT, Kashgarian M, Hla T, Shapiro LH, Ferrer FA (2018) Cell-intrinsic sphingosine kinase 2 promotes macrophage polarization and renal inflammation in response to unilateral ureteral obstruction. PLoS ONE 13:e0194053. https://doi.org/10.1371/journal.pone.0194053
doi: 10.1371/journal.pone.0194053
pubmed: 29518138
pmcid: 5843290
Glueck M, Koch A, Brunkhorst R, Ferreiros Bouzas N, Trautmann S, Schaefer L, Pfeilschifter W, Pfeilschifter J, Vutukuri R (2022) The atypical sphingosine 1-phosphate variant, d16:1 S1P, mediates CTGF induction via S1P2 activation in renal cell carcinoma. FEBS J 289:5670–5681. https://doi.org/10.1111/febs.16446
doi: 10.1111/febs.16446
pubmed: 35320610
Glueck M, Lucaciu A, Subburayalu J, Kestner RI, Pfeilschifter W, Vutukuri R, Pfeilschifter J (2024) Atypical sphingosine-1-phosphate metabolites—biological implications of alkyl chain length. Pflugers Arch - Eur J Physiol. https://doi.org/10.1007/s00424-024-03018-8
doi: 10.1007/s00424-024-03018-8
Hafizi R, Imeri F, Stepanovska Tanturovska B, Manaila R, Schwalm S, Trautmann S, Wenger RH, Pfeilschifter J, Huwiler A (2022) Sphk1 and Sphk2 differentially regulate erythropoietin synthesis in mouse renal interstitial fibroblast-like cells. Int J Mol Sci 23:5882. https://doi.org/10.3390/ijms23115882
doi: 10.3390/ijms23115882
pubmed: 35682566
pmcid: 9180811
Hafizi R, Imeri F, Wenger RH, Huwiler A (2021) S1P stimulates erythropoietin production in mouse renal interstitial fibroblasts by S1P1 and S1P3 receptor activation and HIF-2α stabilization. Int J Mol Sci 22:9467. https://doi.org/10.3390/ijms22179467
doi: 10.3390/ijms22179467
pubmed: 34502385
pmcid: 8430949
Hammad SM, Hunt KJ, Baker NL, Klein RL, Lopes-Virella MF (2022) Diabetes and kidney dysfunction markedly alter the content of sphingolipids carried by circulating lipoproteins. J Clin Lipidol 16:173–183. https://doi.org/10.1016/j.jacl.2021.12.004
doi: 10.1016/j.jacl.2021.12.004
pubmed: 35148982
Hatoum D, Haddadi N, Lin Y, Nassif NT, McGowan EM (2017) Mammalian sphingosine kinase (SphK) isoenzymes and isoform expression: challenges for SphK as an oncotarget. Oncotarget 8:36898–36929. https://doi.org/10.18632/oncotarget.16370
doi: 10.18632/oncotarget.16370
pubmed: 28415564
pmcid: 5482707
Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu Z-H, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R (2023) Empagliflozin in patients with chronic kidney disease. N Engl J Med 388:117–127. https://doi.org/10.1056/NEJMoa2204233
doi: 10.1056/NEJMoa2204233
pubmed: 36331190
Houssiau FA (2011) Toward better treatment for lupus nephritis. N Engl J Med 365:1929–1930. https://doi.org/10.1056/NEJMe1111089
doi: 10.1056/NEJMe1111089
pubmed: 22087685
Huang J, Li J, Chen Z, Li J, Chen Q, Gong W, Liu P, Huang H (2017) Sphingosine kinase 1 mediates diabetic renal fibrosis via NF-κB signaling pathway: involvement of CK2α. Oncotarget 8:88988
doi: 10.18632/oncotarget.21640
pubmed: 29179493
pmcid: 5687663
Huwiler A, Pfeilschifter J (2018) Sphingolipid signaling in renal fibrosis. Matrix Biol 68–69:230–247. https://doi.org/10.1016/j.matbio.2018.01.006
doi: 10.1016/j.matbio.2018.01.006
pubmed: 29343457
Huwiler A, Zangemeister-Wittke U (2018) The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: recent findings and new perspectives. Pharmacol Ther 185:34–49. https://doi.org/10.1016/j.pharmthera.2017.11.001
doi: 10.1016/j.pharmthera.2017.11.001
pubmed: 29127024
Imeri F, Stepanovska Tanturovska B, Manaila R, Pavenstädt H, Pfeilschifter J, Huwiler A (2023) Loss of S1P lyase expression in human podocytes causes a reduction in nephrin expression that involves PKCδ activation. Int J Mol Sci 24:3267. https://doi.org/10.3390/ijms24043267
doi: 10.3390/ijms24043267
pubmed: 36834691
pmcid: 9965238
Imeri F, Stepanovska Tanturovska B, Schwalm S, Saha S, Zeng-Brouwers J, Pavenstädt H, Pfeilschifter J, Schaefer L, Huwiler A (2021) Loss of sphingosine kinase 2 enhances Wilm’s tumor suppressor gene 1 and nephrin expression in podocytes and protects from streptozotocin-induced podocytopathy and albuminuria in mice. Matrix Biol 98:32–48. https://doi.org/10.1016/j.matbio.2021.05.003
doi: 10.1016/j.matbio.2021.05.003
pubmed: 34015468
Inoue T, Nakamura Y, Tanaka S, Kohro T, Li LX, Huang L, Yao J, Kawamura S, Inoue R, Nishi H, Fukaya D, Uni R, Hasegawa S, Inagi R, Umene R, Wu C-H, Ye H, Bajwa A, Rosin DL, Ishihara K, Nangaku M, Wada Y, Okusa MD (2022) Bone marrow stromal cell antigen-1 (CD157) regulated by sphingosine kinase 2 mediates kidney fibrosis. Front Med (Lausanne) 9:993698. https://doi.org/10.3389/fmed.2022.993698
doi: 10.3389/fmed.2022.993698
pubmed: 36267620
Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V (2021) Chronic kidney disease. The Lancet 398:786–802. https://doi.org/10.1016/S0140-6736(21)00519-5
doi: 10.1016/S0140-6736(21)00519-5
Kaur H, Yerra VG, Batchu SN, Tran DT, Kabir MDG, Liu Y, Advani SL, Sedrak P, Geldenhuys L, Tennankore KK, Poyah P, Siddiqi FS, Advani A (2023) Single cell G-protein coupled receptor profiling of activated kidney fibroblasts expressing transcription factor 21. Br J Pharmacol 180:2898–2915. https://doi.org/10.1111/bph.16101
doi: 10.1111/bph.16101
pubmed: 37115600
Kharel Y, Huang T, Salamon A, Harris TE, Santos WL, Lynch KR (2020) Mechanism of sphingosine 1-phosphate clearance from blood. Biochem J 477:925–935. https://doi.org/10.1042/BCJ20190730
doi: 10.1042/BCJ20190730
pubmed: 32065229
Kharel Y, Raje M, Gao M, Gellett AM, Tomsig JL, Lynch KR, Santos WL (2012) Sphingosine kinase type 2 inhibition elevates circulating sphingosine 1-phosphate. Biochem J 447:149–157. https://doi.org/10.1042/BJ20120609
doi: 10.1042/BJ20120609
pubmed: 22747486
Kihara A (2014) Sphingosine 1-phosphate is a key metabolite linking sphingolipids to glycerophospholipids. Biochim Biophys Acta (BBA) – Mol Cell Biol Lipids 1841:766–772. https://doi.org/10.1016/j.bbalip.2013.08.014
doi: 10.1016/j.bbalip.2013.08.014
Kurano M, Tsukamoto K, Shimizu T, Hara M, Yatomi Y (2023) Apolipoprotein M/sphingosine 1-phosphate protects against diabetic nephropathy. Transl Res 258:16–34
doi: 10.1016/j.trsl.2023.02.004
pubmed: 36805561
Kurano M, Tsuneyama K, Morimoto Y, Nishikawa M, Yatomi Y (2019) Apolipoprotein M suppresses the phenotypes of IgA nephropathy in hyper-IgA mice. FASEB J 33:5181–5195. https://doi.org/10.1096/fj.201801748R
doi: 10.1096/fj.201801748R
pubmed: 30629456
Lai KN, Tang SCW, Schena FP, Novak J, Tomino Y, Fogo AB, Glassock RJ (2016) IgA nephropathy. Nat Rev Dis Primers 2:1–20. https://doi.org/10.1038/nrdp.2016.1
doi: 10.1038/nrdp.2016.1
Lech M, Anders H-J (2013) The pathogenesis of lupus nephritis. J Am Soc Nephrol 24:1357–1366. https://doi.org/10.1681/ASN.2013010026
doi: 10.1681/ASN.2013010026
pubmed: 23929771
pmcid: 3752952
Levey A, Coresh J (2012) Chronic kidney disease. The Lancet 379:165–180. https://doi.org/10.1016/S0140-6736(11)60178-5
doi: 10.1016/S0140-6736(11)60178-5
Li A-P, Yang L, Zhang L-C, He S-S, Jia J-P, Qin X-M (2020) Evaluation of injury degree of adriamycin-induced nephropathy in rats based on serum metabolomics combined with proline marker. J Proteome Res 19:2575–2584. https://doi.org/10.1021/acs.jproteome.9b00785
doi: 10.1021/acs.jproteome.9b00785
pubmed: 31887047
Li L, Fu H, Liu Y (2022) The fibrogenic niche in kidney fibrosis: components and mechanisms. Nat Rev Nephrol 18:545–557. https://doi.org/10.1038/s41581-022-00590-z
doi: 10.1038/s41581-022-00590-z
pubmed: 35788561
Li X, Wu M, Chen L, Lu J, Li G, Fu L, Qi N, Lin Y, Sun Z, Wang X, Zhang H, Liu J, Jiang H, Li L, Mei C-L, Luo C (2020) A sphingosine-1-phosphate modulator ameliorates polycystic kidney disease in han: SPRD rats. Am J Nephrol 51:1–10. https://doi.org/10.1159/000502855
doi: 10.1159/000502855
pubmed: 31694015
Liu G, Wang Q, Shi Y, Peng X, Liu H, Peng Y, He L (2017) Resveratrol attenuates adriamycin-induced focal segmental glomerulosclerosis through C3aR/C5aR- sphingosine kinase 1 pathway. Pharmacology 100:253–260. https://doi.org/10.1159/000479525
doi: 10.1159/000479525
pubmed: 28797008
Lovric S, Goncalves S, Gee HY, Oskouian B, Srinivas H, Choi W-I, Shril S, Ashraf S, Tan W, Rao J, Airik M, Schapiro D, Braun DA, Sadowski CE, Widmeier E, Jobst-Schwan T, Schmidt JM, Girik V, Capitani G, Suh JH, Lachaussée N, Arrondel C, Patat J, Gribouval O, Furlano M, Boyer O, Schmitt A, Vuiblet V, Hashmi S, Wilcken R, Bernier FP, Innes AM, Parboosingh JS, Lamont RE, Midgley JP, Wright N, Majewski J, Zenker M, Schaefer F, Kuss N, Greil J, Giese T, Schwarz K, Catheline V, Schanze D, Franke I, Sznajer Y, Truant AS, Adams B, Désir J, Biemann R, Pei Y, Ars E, Lloberas N, Madrid A, Dharnidharka VR, Connolly AM, Willing MC, Cooper MA, Lifton RP, Simons M, Riezman H, Antignac C, Saba JD, Hildebrandt F (2017) Mutations in sphingosine-1-phosphate lyase cause nephrosis with ichthyosis and adrenal insufficiency. J Clin Invest 127:912–928. https://doi.org/10.1172/JCI89626
doi: 10.1172/JCI89626
pubmed: 28165339
pmcid: 5330730
Luo R, Cheng Y, Chang D, Liu T, Liu L, Pei G, Zhang N, Wang Z, Guo K, Chen W, Li M, Fan L, Zhang C, Li Y, Dai W, Zuo M, Xu Y, Yao Y, Ge S, Xu G (2021) Tertiary lymphoid organs are associated with the progression of kidney damage and regulated by interleukin-17A. Theranostics 11:117. https://doi.org/10.7150/thno.48624
doi: 10.7150/thno.48624
pubmed: 33391465
pmcid: 7681089
Maceyka M, Sankala H, Hait NC, Le Stunff H, Liu H, Toman R, Collier C, Zhang M, Satin LS, Merrill AH, Milstien S, Spiegel S (2005) SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J Biol Chem 280:37118–37129. https://doi.org/10.1074/jbc.M502207200
doi: 10.1074/jbc.M502207200
pubmed: 16118219
McNaughton M, Pitman M, Pitson SM, Pyne NJ, Pyne S (2016) Proteasomal degradation of sphingosine kinase 1 and inhibition of dihydroceramide desaturase by the sphingosine kinase inhibitors, SKi or ABC294640, induces growth arrest in androgen-independent LNCaP-AI prostate cancer cells. Oncotarget 7:16663–16675. https://doi.org/10.18632/oncotarget.7693
doi: 10.18632/oncotarget.7693
pubmed: 26934645
pmcid: 4941342
Mirzaian M, Wisse P, Ferraz MJ, Marques ARA, Gabriel TL, van Roomen CPAA, Ottenhoff R, van Eijk M, Codée JDC, van der Marel GA, Overkleeft HS, Aerts JM (2016) Accurate quantification of sphingosine-1-phosphate in normal and Fabry disease plasma, cells and tissues by LC-MS/MS with (13)C-encoded natural S1P as internal standard. Clin Chim Acta 459:36–44. https://doi.org/10.1016/j.cca.2016.05.017
doi: 10.1016/j.cca.2016.05.017
pubmed: 27221202
Mizugishi K, Yamashita T, Olivera A, Miller GF, Spiegel S, Proia RL (2005) Essential role for sphingosine kinases in neural and vascular development. Mol Cell Biol 25:11113–11121. https://doi.org/10.1128/MCB.25.24.11113-11121.2005
doi: 10.1128/MCB.25.24.11113-11121.2005
pubmed: 16314531
pmcid: 1316977
Mok CC, Kwok RCL, Yip PSF (2013) Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum 65:2154–2160. https://doi.org/10.1002/art.38006
doi: 10.1002/art.38006
pubmed: 23754671
Morand EF, Fernandez-Ruiz R, Blazer A, Niewold TB (2023) Advances in the management of systemic lupus erythematosus. BMJ 383:e073980. https://doi.org/10.1136/bmj-2022-073980
doi: 10.1136/bmj-2022-073980
pubmed: 37884289
Nagahashi M, Kim EY, Yamada A, Ramachandran S, Allegood JC, Hait NC, Maceyka M, Milstien S, Takabe K, Spiegel S (2013) Spns2, a transporter of phosphorylated sphingoid bases, regulates their blood and lymph levels, and the lymphatic network. FASEB J 27:1001–1011. https://doi.org/10.1096/fj.12-219618
doi: 10.1096/fj.12-219618
pubmed: 23180825
pmcid: 3574288
Nishi T, Kobayashi N, Hisano Y, Kawahara A, Yamaguchi A (2014) Molecular and physiological functions of sphingosine 1-phosphate transporters. Biochim Biophys Acta (BBA) – Mol Cell Biol Lipids 1841:759–765. https://doi.org/10.1016/j.bbalip.2013.07.012
doi: 10.1016/j.bbalip.2013.07.012
Nojiri T, Kurano M, Tokuhara Y, Ohkubo S, Hara M, Ikeda H, Tsukamoto K, Yatomi Y (2014) Modulation of sphingosine-1-phosphate and apolipoprotein M levels in the plasma, liver and kidneys in streptozotocin-induced diabetic mice. J Diabetes Investig 5:639–648. https://doi.org/10.1111/jdi.12232
doi: 10.1111/jdi.12232
pubmed: 25422763
pmcid: 4234226
Okazaki H, Hirata D, Kamimura T, Sato H, Iwamoto M, Yoshio T, Masuyama J, Fujimura A, Kobayashi E, Kano S, Minota S (2002) Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus. J Rheumatol 29:707–716
pubmed: 11950011
Pan Y, Yang H, Chen T, Jin J, Ruan L, Hu L, Chen L (2022) Extracellular vesicles metabolic changes reveals plasma signature in stage-dependent diabetic kidney disease. Ren Fail 44:1850–1859. https://doi.org/10.1080/0886022X.2022.2118067
doi: 10.1080/0886022X.2022.2118067
pmcid: 9662026
Panizo S, Martínez-Arias L, Alonso-Montes C, Cannata P, Martín-Carro B, Fernández-Martín JL, Naves-Díaz M, Carrillo-López N, Cannata-Andía JB (2021) Fibrosis in chronic kidney disease: pathogenesis and consequences. Int J Mol Sci 22:408. https://doi.org/10.3390/ijms22010408
doi: 10.3390/ijms22010408
pubmed: 33401711
pmcid: 7795409
Parikh SV, Almaani S, Brodsky S, Rovin BH (2020) Update on lupus nephritis: core curriculum 2020. Am J Kidney Dis 76:265–281. https://doi.org/10.1053/j.ajkd.2019.10.017
doi: 10.1053/j.ajkd.2019.10.017
pubmed: 32220510
Patwardhan NN, Morris EA, Kharel Y, Raje MR, Gao M, Tomsig JL, Lynch KR, Santos WL (2015) Structure-activity relationship studies and in vivo activity of guanidine-based sphingosine kinase inhibitors: discovery of SphK1- and SphK2-selective inhibitors. J Med Chem 58:1879–1899. https://doi.org/10.1021/jm501760d
doi: 10.1021/jm501760d
pubmed: 25643074
pmcid: 4557804
Patyna S, Büttner S, Eckes T, Obermüller N, Bartel C, Braner A, Trautmann S, Thomas D, Geiger H, Pfeilschifter J, Koch A (2019) Blood ceramides as novel markers for renal impairment in systemic lupus erythematosus. Prostaglandins Other Lipid Mediat 144:106348. https://doi.org/10.1016/j.prostaglandins.2019.106348
doi: 10.1016/j.prostaglandins.2019.106348
pubmed: 31301404
Pérez-Villavicencio R, Flores-Estrada J, Franco M, Escalante B, Pérez-Méndez O, Mercado A, Bautista-Pérez R (2022) Effect of empagliflozin on sphingolipid catabolism in diabetic and hypertensive rats. Int J Mol Sci 23:2883. https://doi.org/10.3390/ijms23052883
doi: 10.3390/ijms23052883
pubmed: 35270028
pmcid: 8910883
Perry HM, Huang L, Ye H, Liu C, Sung SJ, Lynch KR, Rosin DL, Bajwa A, Okusa MD (2016) Endothelial sphingosine 1-phosphate receptor-1 mediates protection and recovery from acute kidney injury. J Am Soc Nephrol 27:3383–3393. https://doi.org/10.1681/ASN.2015080922
doi: 10.1681/ASN.2015080922
pubmed: 26961351
pmcid: 5084889
Platt FM, d’Azzo A, Davidson BL, Neufeld EF, Tifft CJ (2018) Lysosomal storage diseases. Nat Rev Dis Primers 4:27. https://doi.org/10.1038/s41572-018-0025-4
doi: 10.1038/s41572-018-0025-4
pubmed: 30275469
Poirier B, Briand V, Kadereit D, Schäfer M, Wohlfart P, Philippo M-C, Caillaud D, Gouraud L, Grailhe P, Bidouard J-P, Trellu M, Muslin AJ, Janiak P, Parkar AA (2020) A G protein-biased S1P1 agonist, SAR247799, protects endothelial cells without affecting lymphocyte numbers. Sci Signal 13:eaax8050. https://doi.org/10.1126/scisignal.aax8050
doi: 10.1126/scisignal.aax8050
pubmed: 32487716
Polzin A, Helten C, Dannenberg L, Müller T, Gräler M, Kelm M, Levkau B (2021) Sphingosine-1-phosphate: a mediator of the ARB-MI paradox? Int J Cardiol 333:40–42. https://doi.org/10.1016/j.ijcard.2021.02.082
doi: 10.1016/j.ijcard.2021.02.082
pubmed: 33675892
Ponticelli C, Locatelli F (2018) Glucocorticoids in the treatment of glomerular diseases. Clin J Am Soc Nephrol 13:815–822. https://doi.org/10.2215/CJN.12991117
doi: 10.2215/CJN.12991117
pubmed: 29475991
pmcid: 5969489
Prell A, Wigger D, Huwiler A, Schumacher F, Kleuser B (2024) The sphingosine kinase 2 inhibitors ABC294640 and K145 elevate (dihydro)sphingosine 1-phosphate levels in various cells. J Lipid Res 100631. https://doi.org/10.1016/j.jlr.2024.100631
Proia RL, Hla T (2015) Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy. J Clin Invest 125:1379–1387. https://doi.org/10.1172/JCI76369
doi: 10.1172/JCI76369
pubmed: 25831442
pmcid: 4409021
Pyne NJ, Dubois G, Pyne S (2013) Role of sphingosine 1-phosphate and lysophosphatidic acid in fibrosis. Biochim Biophys Acta 1831:228–238. https://doi.org/10.1016/j.bbalip.2012.07.003
doi: 10.1016/j.bbalip.2012.07.003
pubmed: 22801038
Pyne S, Adams DR, Pyne NJ (2016) Sphingosine 1-phosphate and sphingosine kinases in health and disease: recent advances. Prog Lipid Res 62:93–106. https://doi.org/10.1016/j.plipres.2016.03.001
doi: 10.1016/j.plipres.2016.03.001
pubmed: 26970273
Rajasekaran A, Julian BA, Rizk DV (2021) IgA nephropathy: an interesting autoimmune kidney disease. Am J Med Sci 361:176–194. https://doi.org/10.1016/j.amjms.2020.10.003
doi: 10.1016/j.amjms.2020.10.003
pubmed: 33309134
Ren S, Babelova A, Moreth K, Xin C, Eberhardt W, Doller A, Pavenstädt H, Schaefer L, Pfeilschifter J, Huwiler A (2009) Transforming growth factor-beta2 upregulates sphingosine kinase-1 activity, which in turn attenuates the fibrotic response to TGF-beta2 by impeding CTGF expression. Kidney Int 76:857–867. https://doi.org/10.1038/ki.2009.297
doi: 10.1038/ki.2009.297
pubmed: 19657322
Ripoll CV, Guo Z, Kumari T, Girardi A, Diab A, Özcan M, He L, Oscarsson J, Esterline R, Schilling J, Kosiborod M, Cho J, Javaheri A (2022) Dapagliflozin improves endothelial integrity and cardiac loading through a sphingosine-1-phosphate/apolipoprotein M dependent pathway. J Cardiac Fail 28:S3. https://doi.org/10.1016/j.cardfail.2022.03.010
doi: 10.1016/j.cardfail.2022.03.010
Rodrigues JC, Haas M, Reich HN (2017) IgA nephropathy. Clin J Am Soc Nephrol 12:677. https://doi.org/10.2215/CJN.07420716
doi: 10.2215/CJN.07420716
pubmed: 28159829
pmcid: 5383386
Romagnani P, Remuzzi G, Glassock R, Levin A, Jager K, Tonelli M, Massy Z, Wanner C, Anders H (2017) Chronic kidney disease. Nat Rev Dis Prim 3. https://doi.org/10.1038/nrdp.2017.88
Rousselle TV, Kuscu C, Kuscu C, Schlegel K, Huang L, Namwanje M, Eason JD, Makowski L, Maluf D, Mas V, Bajwa A (2020) FTY720 regulates mitochondria biogenesis in dendritic cells to prevent kidney ischemic reperfusion injury. Front Immunol 11. https://doi.org/10.3389/fimmu.2020.01278
Ruiz-Ortega M, Rupérez M, Esteban V, Rodríguez-Vita J, Sánchez-López E, Carvajal G, Egido J (2006) Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol Dial Transplant 21:16–20. https://doi.org/10.1093/ndt/gfi265
doi: 10.1093/ndt/gfi265
pubmed: 16280370
Schümann J, Grevot A, Ledieu D, Wolf A, Schubart A, Piaia A, Sutter E, Côté S, Beerli C, Pognan F, Billich A, Moulin P, Walker UJ (2015) Reduced activity of sphingosine-1-phosphate lyase induces podocyte-related glomerular proteinuria, skin irritation, and platelet activation. Toxicol Pathol 43:694–703. https://doi.org/10.1177/0192623314565650
doi: 10.1177/0192623314565650
pubmed: 25630683
Schwalm S, Beyer S, Frey H, Haceni R, Grammatikos G, Thomas D, Geisslinger G, Schaefer L, Huwiler A, Pfeilschifter J (2017) Sphingosine kinase-2 deficiency ameliorates kidney fibrosis by up-regulating Smad7 in a mouse model of unilateral ureteral obstruction. Am J Pathol 187:2413–2429
doi: 10.1016/j.ajpath.2017.06.017
pubmed: 28807595
Schwalm S, Beyer S, Hafizi R, Trautmann S, Geisslinger G, Adams DR, Pyne S, Pyne N, Schaefer L, Huwiler A, Pfeilschifter J (2021) Validation of highly selective sphingosine kinase 2 inhibitors SLM6031434 and HWG-35D as effective anti-fibrotic treatment options in a mouse model of tubulointerstitial fibrosis. Cell Signal 79:109881. https://doi.org/10.1016/j.cellsig.2020.109881
doi: 10.1016/j.cellsig.2020.109881
pubmed: 33301900
Schwalm S, Pfeilschifter J, Huwiler A (2013) Sphingosine-1-phosphate: a Janus-faced mediator of fibrotic diseases. Biochim Biophys Acta (BBA) – Mol Cell Biol Lipids 1831:239–250. https://doi.org/10.1016/j.bbalip.2012.07.022
doi: 10.1016/j.bbalip.2012.07.022
Schwalm S, Pfeilschifter J, Huwiler A (2014) Targeting the sphingosine kinase/sphingosine 1-phosphate pathway to treat chronic inflammatory kidney diseases. Basic Clin Pharma Tox 114:44–49. https://doi.org/10.1111/bcpt.12103
doi: 10.1111/bcpt.12103
Schwalm S, Timcheva TM, Filipenko I, Ebadi M, Hofmann LP, Zangemeister-Wittke U, Pfeilschifter J, Huwiler A (2015) Sphingosine kinase 2 deficiency increases proliferation and migration of renal mouse mesangial cells and fibroblasts. Biol Chem 396:813–825. https://doi.org/10.1515/hsz-2014-0289
doi: 10.1515/hsz-2014-0289
pubmed: 25781541
Shin S-H, Kim H-Y, Yoon H-S, Park W-J, Adams DR, Pyne NJ, Pyne S, Park J-W (2020) A novel selective sphingosine kinase 2 inhibitor, HWG-35D, ameliorates the severity of imiquimod-induced psoriasis model by blocking Th17 differentiation of naïve CD4 T lymphocytes. Int J Mol Sci 21:8371. https://doi.org/10.3390/ijms21218371
doi: 10.3390/ijms21218371
pubmed: 33171607
pmcid: 7664669
Smith CD, Maines LW, Keller SN, Katz Ben-Yair V, Fathi R, Plasse TF, Levitt ML (2022) Recent progress in the development of opaganib for the treatment of Covid-19. Drug Des Devel Ther 16:2199–2211. https://doi.org/10.2147/DDDT.S367612
doi: 10.2147/DDDT.S367612
pubmed: 35855741
pmcid: 9288228
Snider AJ, Ruiz P, Obeid LM, Oates JC (2013) Inhibition of sphingosine kinase-2 in a murine model of lupus nephritis. PLoS ONE 8:e53521. https://doi.org/10.1371/journal.pone.0053521
doi: 10.1371/journal.pone.0053521
pubmed: 23301082
pmcid: 3536755
Sonn BJ, Saben JL, McWilliams G, Shelton SK, Flaten HK, D’Alessandro A, Monte AA (2019) Predicting response to lisinopril in treating hypertension: a pilot study. Metabolomics 15:133. https://doi.org/10.1007/s11306-019-1601-7
doi: 10.1007/s11306-019-1601-7
pubmed: 31583478
pmcid: 6815665
Spiegel S, Maczis MA, Maceyka M, Milstien S (2019) New insights into functions of the sphingosine-1-phosphate transporter SPNS2. J Lipid Res 60:484–489. https://doi.org/10.1194/jlr.S091959
doi: 10.1194/jlr.S091959
pubmed: 30655317
pmcid: 6399492
Stepanovska B, Huwiler A (2020) Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases. Pharmacol Res 154:104170. https://doi.org/10.1016/j.phrs.2019.02.009
doi: 10.1016/j.phrs.2019.02.009
pubmed: 30776422
Strasser DS, Froidevaux S, Sippel V, Gerossier E, Grieder U, Pierlot GM, Kieninger-Graefitsch A, Vezzali E, Stalder AK, Renault B, Ryge J, Hart A, Mentzel U, Groenen PMA, Keller MP, Trendelenburg M, Martinic MM, Murphy MJ (2020) Preclinical to clinical translation of cenerimod, a novel S1P1 receptor modulator, in systemic lupus erythematosus. RMD Open 6:e001261. https://doi.org/10.1136/rmdopen-2020-001261
doi: 10.1136/rmdopen-2020-001261
pubmed: 32917831
pmcid: 7722385
Su K, Zeng P, Liang W, Luo Z, Wang Y, Lv X, Han Q, Yan M, Chen C (2017) FTY720 attenuates angiotensin II-induced podocyte damage via inhibiting inflammatory cytokines. Mediators Inflamm 2017:3701385. https://doi.org/10.1155/2017/3701385
doi: 10.1155/2017/3701385
pubmed: 28270699
pmcid: 5320072
Sugahara K, Maeda Y, Shimano K, Murase M, Mochiduki S, Takemoto K, Kakimoto T, Utsumi H, Oshita K, Kataoka H (2019) Amiselimod (MT-1303), a novel sphingosine 1-phosphate receptor-1 modulator, potently inhibits the progression of lupus nephritis in two murine SLE models. J Immunol Res 2019:5821589. https://doi.org/10.1155/2019/5821589
doi: 10.1155/2019/5821589
pubmed: 31930150
pmcid: 6942851
Tanaka S, Zheng S, Kharel Y, Fritzemeier RG, Huang T, Foster D, Poudel N, Goggins E, Yamaoka Y, Rudnicka KP, Lipsey JE, Radel HV, Ryuh SM, Inoue T, Yao J, Rosin DL, Schwab SR, Santos WL, Lynch KR, Okusa MD (2022) Sphingosine 1-phosphate signaling in perivascular cells enhances inflammation and fibrosis in the kidney. Sci Transl Med 14:eabj2681. https://doi.org/10.1126/scitranslmed.abj2681
doi: 10.1126/scitranslmed.abj2681
pubmed: 35976996
pmcid: 9873476
Tang L, Wu Y, Tian M, Sjöström CD, Johansson U, Peng X-R, Smith DM, Huang Y (2017) Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes. Am J Physiol-Endocrinol Metab 313:E563–E576. https://doi.org/10.1152/ajpendo.00086.2017
doi: 10.1152/ajpendo.00086.2017
pubmed: 28811292
Taylor Meadows KR, Steinberg MW, Clemons B, Stokes ME, Opiteck GJ, Peach R, Scott FL (2018) Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus. PLoS ONE 13:e0193236. https://doi.org/10.1371/journal.pone.0193236
doi: 10.1371/journal.pone.0193236
pubmed: 29608575
pmcid: 5880347
Tian J, Chang S, Wang J, Chen J, Xu H, Huang T, Wang J, Kang J, Fan W, Wang Y (2023) S1P/S1PR1 axis promotes macrophage M1 polarization through NLRP3 inflammasome activation in lupus nephritis. Mol Immunol 160:55–66. https://doi.org/10.1016/j.molimm.2023.06.006
doi: 10.1016/j.molimm.2023.06.006
pubmed: 37379683
Tian T, Zhang J, Zhu X, Wen S, Shi D, Zhou H (2017) FTY720 ameliorates renal fibrosis by simultaneously affecting leucocyte recruitment and TGF-β signalling in fibroblasts. Clin Exp Immunol 190:68–78. https://doi.org/10.1111/cei.13003
doi: 10.1111/cei.13003
pubmed: 28658504
pmcid: 5588762
Vu TM, Ishizu A-N, Foo JC, Toh XR, Zhang F, Whee DM, Torta F, Cazenave-Gassiot A, Matsumura T, Kim S, Toh S-AES, Suda T, Silver DL, Wenk MR, Nguyen LN (2017) Mfsd2b is essential for the sphingosine-1-phosphate export in erythrocytes and platelets. Nature 550:524–528. https://doi.org/10.1038/nature24053
doi: 10.1038/nature24053
pubmed: 29045386
W C, H X, R C, J Y, X Y, J Z, H L, S Z, J X, P C, Af C, S C, H L (2019) S1PR2 antagonist ameliorate high glucose-induced fission and dysfunction of mitochondria in HRGECs via regulating ROCK1. BMC nephrology 20. https://doi.org/10.1186/s12882-019-1323-0
Watson L, Tullus K, Marks SD, Holt RCL, Pilkington C, Beresford MW (2012) Increased serum concentration of sphingosine-1-phosphate in juvenile-onset systemic lupus erythematosus. J Clin Immunol 32:1019–1025. https://doi.org/10.1007/s10875-012-9710-3
doi: 10.1007/s10875-012-9710-3
pubmed: 22648459
Webster AC, Nagler EV, Morton RL, Masson P (2017) Chronic kidney disease. Lancet 389:1238–1252. https://doi.org/10.1016/S0140-6736(16)32064-5
doi: 10.1016/S0140-6736(16)32064-5
pubmed: 27887750
Xie D, Hu G, Chen C, Ahmadinejad F, Wang W, Li P-L, Gewirtz DA, Li N (2022) Loss of sphingosine kinase 2 protects against cisplatin-induced kidney injury. Am J Physiol-Renal Physiol 323:F322–F334. https://doi.org/10.1152/ajprenal.00229.2021
doi: 10.1152/ajprenal.00229.2021
pubmed: 35834271
pmcid: 9394771
Yaghobian D, Don AS, Yaghobian S, Chen X, Pollock CA, Saad S (2016) Increased sphingosine 1-phosphate mediates inflammation and fibrosis in tubular injury in diabetic nephropathy. Clin Exp Pharma Physio 43:56–66. https://doi.org/10.1111/1440-1681.12494
doi: 10.1111/1440-1681.12494
Yang Q, Tang D, Gan C, Bai M, Song X, Jiang W, Li Q, Chen Y, Zhang A, Wang M (2024) Novel variants in CRB2 targeting the malfunction of slit diaphragm related to focal segmental glomerulosclerosis. Pediatr Nephrol 39:149–165. https://doi.org/10.1007/s00467-023-06087-6
doi: 10.1007/s00467-023-06087-6
pubmed: 37452832
Yang T, Li L, Heng C, Sha P, Wang Y, Shen J, Jiang Z, Qian S, Wei C, Yang H, Zhu X, Wang T, Wu M, Wang J, Lu Q, Yin X (2024) Sodium butyrate ameliorated diabetic nephropathy-associated tubulointerstitial inflammation by modulating the tight junctions of renal tubular epithelial cells. Food Funct 15:2628–2644. https://doi.org/10.1039/d2fo00940d
doi: 10.1039/d2fo00940d
pubmed: 38358014
Yu B, Shen K, Li T, Li J, Meng M, Liu W, Tang Q, Zhu T, Wang X, Leung SWS, Shi Y (2023) Glycolytic enzyme PFKFB3 regulates sphingosine 1-phosphate receptor 1 in proangiogenic glomerular endothelial cells under diabetic condition. Am J Physiol Cell Physiol 325:C1354–C1368. https://doi.org/10.1152/ajpcell.00261.2023
doi: 10.1152/ajpcell.00261.2023
pubmed: 37781737
pmcid: 10861147
Zeng J, Huang H, Zhang Y, Lv X, Cheng J, Zou SJ, Han Y, Wang S, Gong L, Peng Z (2023) Dapagliflozin alleviates renal fibrosis in a mouse model of adenine-induced renal injury by inhibiting TGF-β1/MAPK mediated mitochondrial damage. Front Pharmacol 14:1095487. https://doi.org/10.3389/fphar.2023.1095487
doi: 10.3389/fphar.2023.1095487
pubmed: 36959860
pmcid: 10028454
Zhang J, Chen S, Xiang H, Xiao J, Zhao S, Shu Z, Chai Y, Ouyang J, Liu H, Wang X, Quan Q, Fan J, Gao P, Chen AF, Lu H (2023) S1PR2/Wnt3a/RhoA/ROCK1/β-catenin signaling pathway promotes diabetic nephropathy by inducting endothelial mesenchymal transition and impairing endothelial barrier function. Life Sci 328:121853. https://doi.org/10.1016/j.lfs.2023.121853
doi: 10.1016/j.lfs.2023.121853
pubmed: 37307963
Zhu X, Shi D, Cao K, Ru D, Ren J, Rao Z, Chen Y, You Q, Dai C, Liu L, Zhou H (2018) Sphingosine kinase 2 cooperating with Fyn promotes kidney fibroblast activation and fibrosis via STAT3 and AKT. Biochim Biophys Acta (BBA) – Mol Basis Dis 1864:3824–3836. https://doi.org/10.1016/j.bbadis.2018.09.007
doi: 10.1016/j.bbadis.2018.09.007